Daniel E. Geffken - 07 Jul 2022 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Chief Financial Officer
Signature
/s/ Jason L. Langford, Attorney-in-Fact for Daniel E. Geffken
Issuer symbol
PMN
Transactions as of
07 Jul 2022
Net transactions value
$0
Form type
3
Filing time
07 Jul 2022, 19:28:19 UTC
Previous filing
09 Jun 2022
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares 5,852 07 Jul 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Option (right to buy) 07 Jul 2022 Common Shares 8,333 $10.80 Direct F1, F2
holding PMN Option (right to buy) 07 Jul 2022 Common Shares 8,333 $10.80 Direct F1, F3
holding PMN Warrants (right to buy) 07 Jul 2022 Common Shares 1,042 $18.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Conversion or exercise price is in Canadian dollars.
F2 The option agreement provides that 20% of the options vested immediately, with the balance vesting ratably over 36 months. The option was granted on March 1, 2017.
F3 The option agreement provides that the options become exercisable in twelve equal monthly installments beginning one month after the grant. The option was granted on November 12, 2021.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney